Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis.

Abstract:

:Pulmonary arterial hypertension (PAH) patients have distinct disease courses and responses to treatment, but current diagnostic and treatment schemes provide limited insight. We aimed to see if cluster analysis could distinguish clinical phenotypes in PAH. An unbiased cluster analysis was performed on 17 baseline clinical variables of PAH patients from the FREEDOM-M, FREEDOM-C, and FREEDOM-C2 randomized trials of oral treprostinil versus placebo. Participants were either treatment-naïve (FREEDOM-M) or on background therapy (FREEDOM-C, FREEDOM-C2). We tested for association of clusters with outcomes and interaction with respect to treatment. Primary outcome was 6-minute walking distance (6MWD) change. We included 966 participants with 12-week (FREEDOM-M) or 16-week (FREEDOM-C and FREEDOM-C2) follow-up. Four patient clusters were identified. Compared with Clusters 1 (n = 131) and 2 (n = 496), Clusters 3 (n = 246) and 4 (n = 93) patients were older, heavier, had worse baseline functional class, 6MWD, Borg Dyspnea Index, and fewer years since PAH diagnosis. Clusters also differed by PAH etiology and background therapies, but not gender or race. Mean treatment effect of oral treprostinil differed across Clusters 1-4 increased in a monotonic fashion (Cluster 1: 10.9 m; Cluster 2: 13.0 m; Cluster 3: 25.0 m; Cluster 4: 50.9 m; interaction P value = 0.048). We identified four distinct clusters of PAH patients based on common patient characteristics. Patients who were older, diagnosed with PAH for a shorter period, and had worse baseline symptoms and exercise capacity had the greatest response to oral treprostinil treatment.

journal_name

Pulm Circ

journal_title

Pulmonary circulation

authors

Parikh KS,Rao Y,Ahmad T,Shen K,Felker GM,Rajagopal S

doi

10.1177/2045893217705891

subject

Has Abstract

pub_date

2017-04-01 00:00:00

pages

486-493

issue

2

eissn

2045-8932

issn

2045-8940

journal_volume

7

pub_type

杂志文章
  • Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.

    abstract::Riociguat is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Some patients have difficulty swallowing tablets; therefore, 2 randomized, nonblinded, crossover studies compared the relative bioavailability of riociguat oral suspensions and immediate-releas...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/685020

    authors: Saleh S,Frey R,Becker C,Unger S,Wensing G,Mück W

    更新日期:2016-03-01 00:00:00

  • Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy.

    abstract::Little is known about the impact of metabolic syndrome (MS) on right ventricular (RV) structure and function. We hypothesized that mice fed a Western diet (WD) would develop RV lipid accumulation and impaired RV function, which would be ameliorated with metformin. Male C57/Bl6 mice were fed a WD or standard rodent die...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018817741

    authors: Brittain EL,Talati M,Fortune N,Agrawal V,Meoli DF,West J,Hemnes AR

    更新日期:2019-01-01 00:00:00

  • Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension.

    abstract::Right ventricular failure (RVF) is the most important prognostic factor for both morbidity and mortality in pulmonary arterial hypertension (PAH), but also occurs in numerous other common diseases and conditions, including left ventricle dysfunction. RVF remains understudied compared with left ventricular failure (LVF...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045893217714463

    authors: Samson N,Paulin R

    更新日期:2017-07-01 00:00:00

  • Survey of practices in relation to chronic pulmonary hypertension in neonates in the Canadian Neonatal Network and the National Institute of Child Health and Human Development Neonatal Research Network.

    abstract::Current knowledge gaps pertaining to diagnosis and management of neonatal chronic pulmonary hypertension (cPH) may result in significant variability in clinical practice. The objective of the study is to understand cPH management practices in neonatal intensive care units affiliated with the Canadian Neonatal Network ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894020937126

    authors: Baczynski M,Bell EF,Finan E,McNamara PJ,Jain A

    更新日期:2020-07-16 00:00:00

  • Change in R wave in lead V1 predicts survival of patients with pulmonary arterial hypertension.

    abstract::Clinical guidelines for pulmonary hypertension recommend evaluating treatment response through various methods; however, electrocardiography (ECG) is not included as one of the methods of choice. We aimed to identify ECG parameters that correlated with prognosis in patients with pulmonary arterial hypertension (PAH). ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018776496

    authors: Sato S,Ogawa A,Matsubara H

    更新日期:2018-04-01 00:00:00

  • Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension.

    abstract::N-terminal pro B-type natriuretic peptide (NT-proBNP) is a product of cleavage of the cardiac prohormone pro B-type natriuretic peptide into its active form. It has proven to be a useful biomarker in left heart failure. However, studies examining the utility of serial measurements of NT-proBNP in pulmonary arterial hy...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.4103/2045-8932.83450

    authors: Soon E,Doughty NJ,Treacy CM,Ross RM,Toshner M,Upton PD,Sheares K,Morrell NW,Pepke-Zaba J

    更新日期:2011-04-01 00:00:00

  • "Anagrelide-induced pulmonary arterial hypertension": a rare case of drug-induced pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension can be associated with exposure to certain drugs or toxins. However, only a few cases of drug-induced pulmonary arterial hypertension have been previously reported. Anagrelide is an oral imidazoquinazoline agent that is prescribed for reducing elevated platelet counts in patients with m...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1177/2045894019896682

    authors: Sumimoto K,Taniguchi Y,Matsuoka Y,Onishi H,Emoto N,Hirata KI

    更新日期:2019-12-27 00:00:00

  • Pulmonary tumor thrombotic microangiopathy: a systematic review.

    abstract::Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal disease process in which pulmonary hypertension (PH) develops in the setting of malignancy. The purpose of this study is to present a detailed analysis of cases of PTTM reported in literature in the hopes of achieving more ante-mortem diagnoses. We conducted...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894019851000

    authors: Godbole RH,Saggar R,Kamangar N

    更新日期:2019-04-01 00:00:00

  • An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.

    abstract::Inhaled treprostinil (Tyvaso) has been shown to be a safe and effective addition to pulmonary arterial hypertension (PAH) oral therapies; however, the respiratory-related safety profile of inhaled treprostinil required further elucidation in the setting of routine clinical care. The objectives of this study were to ch...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/688059

    authors: Zamanian RT,Levine DJ,Bourge RC,De Souza SA,Rosenzweig EB,Alnuaimat H,Burger C,Mathai SC,Leedom N,DeAngelis K,Lim A,De Marco T

    更新日期:2016-09-01 00:00:00

  • Compensated right ventricular function of the onset of pulmonary hypertension in a rat model depends on chamber remodeling and contractile augmentation.

    abstract::Right-ventricular function is a good indicator of pulmonary arterial hypertension (PAH) prognosis; however, how the right ventricle (RV) adapts to the pressure overload is not well understood. Here, we aimed at characterizing the time course of RV early remodeling and discriminate the contribution of ventricular geome...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018800439

    authors: Vélez-Rendón D,Zhang X,Gerringer J,Valdez-Jasso D

    更新日期:2018-10-01 00:00:00

  • Non-invasive right ventricular load adaptability indices in patients with scleroderma-associated pulmonary arterial hypertension.

    abstract::Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is associated with worse outcome than idiopathic pulmonary arterial hypertension (IPAH), potentially due to worse right ventricular adaptation to load as suggested by pressure-volume loop analysis. The value of non-invasive load-adaptability metrics has ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018788268

    authors: French S,Amsallem M,Ouazani N,Li S,Kudelko K,Zamanian RT,Haddad F,Chung L

    更新日期:2018-07-01 00:00:00

  • CREB depletion in smooth muscle cells promotes medial thickening, adventitial fibrosis and elicits pulmonary hypertension.

    abstract::Levels of the cAMP-responsive transcription factor, CREB, are reduced in medial smooth muscle cells in remodeled pulmonary arteries from hypertensive calves and rats with chronic hypoxia-induced pulmonary hypertension. Here, we show that chronic hypoxia fails to promote CREB depletion in pulmonary artery smooth muscle...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894019898374

    authors: Garat CV,Majka SM,Sullivan TM,Crossno JT Jr,Reusch JEB,Klemm DJ

    更新日期:2020-04-14 00:00:00

  • Atrial arrhythmias in chronic lung disease-associated pulmonary hypertension.

    abstract::Atrial arrhythmias are common during episodes of acute respiratory failure in patients with chronic lung disease-associated pulmonary hypertension. Expert opinion suggests that management of atrial arrhythmias in patients with pulmonary hypertension should aim to restore sinus rhythm. This is clinically challenging in...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章,评审

    doi:10.1177/2045894020910685

    authors: Vahdatpour CA,Luebbert JJ,Palevsky HI

    更新日期:2020-03-09 00:00:00

  • The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study.

    abstract::Patients with chronic thromboembolic pulmonary hypertension (CTEPH) require lifelong anticoagulation therapy. However, the bleeding risk and recurrence of venous thromboembolism (VTE) in CTEPH patients who are administered warfarin have not been adequately evaluated. The purpose of this study was to evaluate the risk ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045893217717258

    authors: Jujo-Sanada T,Tanabe N,Sakao S,Sugiura T,Sekine A,Nishimura R,Suda R,Naito A,Miwa H,Yamamoto K,Sasaki A,Matsumura A,Ema R,Kasai H,Kato F,Tatsumi K

    更新日期:2017-07-01 00:00:00

  • Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial.

    abstract::Inhaled iloprost is an effective therapy for patients with pulmonary arterial hypertension (PAH); however, some patients experience extended inhalation times when using the V10 formulation (10.0 µg/mL) to deliver a 5 -µg dose (at mouthpiece) and are at risk of incomplete inhalations and reduced inhalation frequency. V...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018798921

    authors: Richter MJ,Stollfuß B,Roitenberg A,Kleinjung F,Graeff V,Berghaus S,Müller C,Ghofrani HA

    更新日期:2018-10-01 00:00:00

  • Levosimendan in pulmonary hypertension and right heart failure.

    abstract::Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality. Right ventricular function is the most important predictor of morbidity and mortality in patients suffering from pulmonary hypertension, but currently there are no approved treatments directly supporting the failing right ventricle...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018790905

    authors: Hansen MS,Andersen A,Nielsen-Kudsk JE

    更新日期:2018-07-01 00:00:00

  • Congenital heart disease and pulmonary arterial hypertension in South America (2013 Grover Conference series).

    abstract::South America is a territory of 17,819,100 km(2), where ∼388 million people live in 13 countries. In the region, access to medical assistance (e.g., for treatment of cardiovascular disorders) is relatively easy in metropolitan areas but difficult in remote places such as the Andes and the Amazon. Altitudes up to ∼6,70...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章,评审

    doi:10.1086/676747

    authors: Lopes AA,Flores PC,Diaz GF,Mesquita SM

    更新日期:2014-09-01 00:00:00

  • A non-selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow-derived cells in ameliorating pulmonary hypertension in mice.

    abstract::The aim of this study was to investigate whether a dual endothelin receptor antagonist bosentan modulates the kinetics of bone marrow-derived stem cells in inhibiting the development of pulmonary hypertension. Bone marrow chimeric mice, transplanted with enhanced green fluorescent protein (eGFP)-positive bone marrow m...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894020919355

    authors: Kato T,Mitani Y,Masuya M,Maruyama J,Sawada H,Ohashi H,Ikeyama Y,Otsuki S,Yodoya N,Shinohara T,Miyata E,Zhang E,Katayama N,Shimpo H,Maruyama K,Komada Y,Hirayama M

    更新日期:2020-05-14 00:00:00

  • Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension.

    abstract::This manuscript on endpoints incorporates the broad experience of members of Pulmonary Vascular Research Institute's Innovative Drug Development Initiative as an open debate platform for academia, the pharmaceutical industry and regulatory experts surrounding the future design of clinical trials in pulmonary hypertens...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894020962960

    authors: Sitbon O,Nikkho S,Benza R,Cq Deng C,W Farber H,Gomberg-Maitland M,Hassoun P,Meier C,Pepke-Zaba J,Prasad K,Seeger W,Corris PA

    更新日期:2020-11-18 00:00:00

  • Addition of a bilateral access form of peripheral extracorporeal membrane oxygenation rescued a patient with idiopathic pulmonary arterial hypertension who developed circulatory collapse immediately after childbirth.

    abstract::Pregnancy is not advised for patients with Pulmonary hypertension (PH) because of high risk of PH crisis. However, some patients have undiagnosed idiopathic pulmonary arterial hypertension (IPAH) before pregnancy. Upfront combination therapy has high efficacy for patients with IPAH. However, some patients are unable t...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1177/2045894020910140

    authors: Adachi S,Shimokata S,Yoshida M,Imai R,Nakano Y,Okumura N,Suzuki S,Murohara T,Kondo T

    更新日期:2020-02-28 00:00:00

  • Effects of exercise rehabilitation training on patients with pulmonary hypertension.

    abstract::Pulmonary hypertension (PH) comprises a group of pathophysiological syndromes characterized by elevated pulmonary artery pressure and pulmonary vascular resistance, which lead to right ventricular overload, and even right heart failure. PH has a poor prognosis and severely leads to a decline in quality of life. Histor...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章,评审

    doi:10.1177/2045894020937129

    authors: Zhang X,Xu D

    更新日期:2020-07-07 00:00:00

  • Pulmonary capillary hemangiomatosis: the role of invasive cardiopulmonary exercise testing.

    abstract::Pulmonary capillary hemangiomatosis (PCH) is a rare form of pulmonary arterial hypertension (PAH) characterized by pulmonary capillary proliferation and pseudoinvasion of collagenous septal structures. PCH is often accompanied by veno-occlusive changes and pulmonary hypertensive arterial remodeling. The clinical and p...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1086/682227

    authors: DuBrock HM,Kradin RL,Rodriguez-Lopez JM,Channick RN

    更新日期:2015-09-01 00:00:00

  • Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries.

    abstract::Limited data about the long-term prognosis and response to therapy in pulmonary arterial hypertension patients with World Health Organization functional class I/II symptoms are available. PubMed and Embase were searched for publications of observational registries and randomized, controlled trials in pulmonary arteria...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894020935291

    authors: Kim NH,Fisher M,Poch D,Zhao C,Shah M,Bartolome S

    更新日期:2020-11-25 00:00:00

  • Advancing clinical trial design in pulmonary hypertension.

    abstract::In pulmonary hypertension, as in many other diseases, there is a need for a smarter approach to evaluating new treatments. The traditional randomized controlled trial has served medical science well, but constrains the development of treatments for rare diseases. A workshop was established to consider alternative clin...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.4103/2045-8932.109933

    authors: Grieve AP,Chow SC,Curram J,Dawe S,Harnisch LO,Henig NR,Hung HM,Ivy DD,Kawut SM,Rahbar MH,Xiao S,Wilkins MR

    更新日期:2013-01-01 00:00:00

  • Molecular and functional significance of Ca(2+)-activated Cl(-) channels in pulmonary arterial smooth muscle.

    abstract::Increased peripheral resistance of small distal pulmonary arteries is a hallmark signature of pulmonary hypertension (PH) and is believed to be the consequence of enhanced vasoconstriction to agonists, thickening of the arterial wall due to remodeling, and increased thrombosis. The elevation in arterial tone in PH is ...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章,评审

    doi:10.1086/680189

    authors: Leblanc N,Forrest AS,Ayon RJ,Wiwchar M,Angermann JE,Pritchard HA,Singer CA,Valencik ML,Britton F,Greenwood IA

    更新日期:2015-06-01 00:00:00

  • Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension.

    abstract::Pulmonary hypertension is recognized as a leading cause of morbidity and mortality in patients with sickle cell disease (SCD). We now report benchtop phenotyping from the explanted lungs of the first successful lung transplant in SCD. Pulmonary artery smooth muscle cells (PASMCs) cultured from the explanted lungs were...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/674754

    authors: Rogers NM,Yao M,Sembrat J,George MP,Knupp H,Ross M,Sharifi-Sanjani M,Milosevic J,St Croix C,Rajkumar R,Frid MG,Hunter KS,Mazzaro L,Novelli EM,Stenmark KR,Gladwin MT,Ahmad F,Champion HC,Isenberg JS

    更新日期:2013-12-01 00:00:00

  • Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol.

    abstract::Infection, thrombosis, and catheter dislodgment are well-recognized potential complications of chronic intravenous prostanoid therapy for pulmonary arterial hypertension. As long-term outcomes of pulmonary hypertension patients improve, novel adverse events are likely to arise. We describe the sudden development of un...

    journal_title:Pulmonary circulation

    pub_type:

    doi:10.1177/2045893217748054

    authors: LeVarge BL,Law AC,Murphy B

    更新日期:2018-01-01 00:00:00

  • MicroRNA expression profile of pulmonary artery smooth muscle cells and the effect of let-7d in chronic thromboembolic pulmonary hypertension.

    abstract::Abstract Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition characterized by single or recurrent pulmonary thromboemboli, which promote pulmonary vascular remodeling. MicroRNA (miRNA), is a small, noncoding RNA that is involved in multiple cell processes and functions and may partici...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/674310

    authors: Wang L,Guo LJ,Liu J,Wang W,Yuan JX,Zhao L,Wang J,Wang C

    更新日期:2013-09-01 00:00:00

  • Low-grade albuminuria in pulmonary arterial hypertension.

    abstract::Low-grade albuminuria, determined by the urinary albumin to creatinine ratio, has been linked to systemic vascular dysfunction and is associated with cardiovascular mortality. Pulmonary arterial hypertension is related to mutations in the bone morphogenetic protein receptor type 2, pulmonary vascular dysfunction and i...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1177/2045894018824564

    authors: Nickel NP,de Jesus Perez VA,Zamanian RT,Fessel JP,Cogan JD,Hamid R,West JD,de Caestecker MP,Yang H,Austin ED

    更新日期:2019-04-01 00:00:00

  • Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat.

    abstract::Endothelial nitric oxide synthase (eNOS) plays a major role in maintaining pulmonary vascular homeostasis. Tetrahydrobiopterin (BH4), an essential cofactor that stabilizes the dimerization of eNOS and balances nitric oxide (NO) and superoxide production, may have therapeutic potential in pulmonary hypertension. In the...

    journal_title:Pulmonary circulation

    pub_type: 杂志文章

    doi:10.1086/677361

    authors: Francis BN,Hale A,Channon KM,Wilkins MR,Zhao L

    更新日期:2014-09-01 00:00:00